A nationwide population-based study on the incidence and prognosis of HER2-positive breast cancer eligible for adjuvant pertuzumab in the modern era of neoadjuvant therapy
Antonis Valachis, Xingrong Liu, Balazs Acs, Johan Hartman, Theodoros Foukakis, Alexios Matikas · 2026
Read A nationwide population-based study on the incidence and prognosis of HER2-positive breast cancer eligible for adjuvant pertuzumab in the modern era of neoadjuvant therapy by Antonis Valachis, Xingrong Liu, Balazs Acs, Johan Hartman, Theodoros Foukakis, Alexios Matikas (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13277662.txt.
Description
Antonis Valachis and colleagues chart HER2-positive breast cancer outcomes across Sweden in a 2026 nationwide study. Adding pertuzumab after surgery improves survival for patients whose cancer reached the lymph nodes. The team asked how many patients still qualify for it as pre-surgery treatment spreads.
Registry data covered more than 135,000 breast cancer patients treated between 2007 and 2023. About three and a half thousand patients formed the after-surgery cohort, and their share shrank over time. Ten-year survival in that group sat near seventy-two percent, with tumour size and nodal stage driving risk. Patients who cleared all visible cancer before surgery fared excellently, prompting questions about added drug benefit.
Catalog record
| CREATOR | Antonis Valachis, Xingrong Liu, Balazs Acs, Johan Hartman, Theodoros Foukakis, Alexios Matikas |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |